PAD Formulary : Surrey Heartlands
PAD - Prescribing Advisory Database
PLEASE NOTE : This is a development system.

For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.

You are here : Home > PAD Profile : Fostamatinib - Immune thrombocytopenia

PAD Profile : Fostamatinib - Immune thrombocytopenia

Keywords :
bleeding, ITP, haematology, NICE, TA835, tyrosine kinase inhibitor, ITP
Brand Names Include :
Tavlesse

Traffic Light Status

Status 1 of 1.

Status :
Red
Formulations :
  • Not Specified
Trust Alignment :
Primary Care
ASPH
RSFT
SASH
SABP
Links :
BNF NICE SPC
Comments :
No comments returned.
Documents :

Guidelines

No guidelines returned.

Other Drugs

Other Indications

Additional Documents

Type
Document
Review Date
Guidelines (Local)
Chronic Immune Thrombocytopenia (ITP) treatment pathway October 2024.pdf
31 October 2027
Evidence Review
Fostamatinib in ITP NICE TA835 Briefing paper Nov 2022.pdf
Webpage
Fostamatinib for treating refractory chronic immune thrombocytopenia NICE TA835 October 2022

Committee Recommendations

Date
Committee Name
Narrative
04 September 2024
Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)

The Surrey Heartlands Integrated Care System Area Prescribing Committee (APC) approves the updated ITP pathway.

04 January 2023
Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)

The Surrey Heartlands Area Prescribing Committee (APC) approves the use of fostamatinib as recommended by NICE TA835 as an option for treating refractory chronic immune thrombocytopenia (ITP) in adults, only if:

  • they have previously had a thrombopoietin receptor agonist (TPO-RA), or a TPO-RA is unsuitable,
  • the company provides fostamatinib according to the commercial arrangement.

Fostamatinib for this indication will be considered as RED on the traffic light system (treatment should be initiated and continued by specialist clinicians).
Primary care clinicians should be aware that their patient is receiving this medicine and ensure that this is recorded on the patient's medication screen as a hospital-only drug in line with guidance on the PAD. This will also alert the prescriber to potential side effects and interactions with other medicines prescribed in primary care. It will also ensure that GP records, which are accessed by other healthcare providers, are a true and accurate reflection of the patient's medication.

Associated BNF Codes

09. Nutrition and Blood
09.01.04. Drugs used in platelet disorders
This site uses its own and third party cookies to function properly and to improve performance, to maintain the session and to personalise user experience, as well as to obtain anonymous statistics about the use of the website. Visit our Privacy and Cookie Policy for more information on our data collection practices. By clicking 'Accept' you agree to our use of cookies for the purposes listed.
 Learn More